HDAC9 and non-small cell lung carcinoma: Furthermore, tumor gene expression array analysis has been performed in a study with the HDAC inhibitor panobinostat as single agent [38] and in one trial each of combining either vorinostat or valproate with other biologic agents (in non-small cell lung carcinoma and acute myeloid leukemia, respectively) [39], [40].